The Patent Finder

Immedica Pharma US Inc.

Also on record
Records under this name other than the patents Immedica Pharma US Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 28 patents it holds.

Back to Immedica Pharma US Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 12,673,093Method and Composition for Treating Arginase 1 Deficiency
now held by Immedica Pharma AB
In force
 · Medium confidence
In forceMedium confidence
US 12,331,335Methods for Production of Human Recombinant Arginase 1 and Uses Thereof
now held by Immedica Pharma AB
In force
 · High confidence
In forceHigh confidence
12/115,169Therapeutic Compounds 570
Abandoned
Abandoned Jul 4, 2011
AbandonedAbandoned Jul 4, 2011
17/006,383Methods For Production Of Human Recombinant Arginase 1 And Uses Thereof
Abandoned
Abandoned Jun 27, 2023
AbandonedAbandoned Jun 27, 2023
18/167,261Injectable Neurosteroid Formulations Containing Nanoparticles
Abandoned
Abandoned Jan 27, 2026
AbandonedAbandoned Jan 27, 2026
18/328,996Use of Ganaxolone in Treating an Epilepsy Disorder
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/591,515Ganaxolone for Use in Treating Tuberous Sclerosis Complex
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/612,277Ganaxolone for Use in Treating Genetic Epileptic Disorders
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/625,718Ganaxolone for Use in Treatment of Established Status Epilepticus
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/731,812Amorphous Solid Dispersion Ganaxolone Formulation
Abandoned
Abandoned Mar 7, 2026
AbandonedAbandoned Mar 7, 2026
10 of 18 records shown.
Pro members see all 18.
Pro members: see all 18 records
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited